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INTRODUCTION
T cells, which are able to recognize myelin basic protein
(MBP), are thought to play a major role in the pathophysi-
ology of experimental autoimmune encephalomyelitis (EAE).
They are activated in the periphery, and then migrate to the
central nervous system (CNS), inducing autoimmune inflam-
mation culminating in motor paralysis (1). B10PL mice, when
immunized with the acetylated N-terminal MBP peptide
(MBP NAc 1-9), were found to generate encephalitogenic
CD4
+ T cell clones, which then migrated to the CNS, induc-
ing EAE. Approximately 85% of encephalitogenic clones express
the T cell receptor (TCR) V 8.2 (2).
Therefore, an ideal therapy for EAE could involve selec-
tive inactivation, elimination, or functional deviation of the
TCR V 8.2. Monoclonal antibodies targeted to pathogenic
V gene products, as well as T-cell vaccination using peptides
from the complementarity-determining regions of the patho-
genic TCR V region, can induce resistance to the develop-
ment of EAE (3). Unfortunately, peptide-based vaccines are
poor immunogens (4). Genetic vaccinations with naked DNA
have been reported to result in long-lasting cellular and humo-
ral immune responses (5), and also, promote a shift in the
pattern of cytokines produced by the pathogenic T cells (6).
Previous studies have indicated that intramuscular injection
of V 8.2 DNA in PL/J mice did not exhibit suppression of
EAE development when they were immunized with whole
MBP (7). The possibility exists that muscle was not consid-
ered to be a viable site for antigen presentation, as it contains
few, if any, dendritic cells, macrophages, and lymphocytes
(8). Furthermore, it has been well established that skin-asso-
ciated lymphoid tissues harbor specialized cells which enhance
immune responses, and that intradermal gene administration
induces more profound immune responses than does intra-
muscular gene delivery (5). Therefore, the in vivo transfection
of epidermal or dermal cells with DNA would be expected
to constitute an efficient route for gene immunization. This
study was undertaken to determine the suppressive effects
of intradermal gene vaccination with plasmid DNA encod-
ing for V 8.2 on the clinical outcome of EAE after immu-
nization with whole rat MBP. 
MATERIALS AND METHODS
Animals
The 40 female B10.PL mice used in this study were obtain-
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The Effects of Intradermal Vaccination with DNA Encoding for the 
T-cell Receptor on the Induction of Experimental Autoimmune
Encephalomyelitis in B10.PL Mice
Intradermal gene administration was found to induce a more profound immune
response than direct intramusclular gene injection. We performed intradermal vac-
cination of B10.PL mice with DNA encoding for the V 8.2 region of the T-cell recep-
tors (TCR). Three weeks later, these mice were immunized with rat myelin basic
protein (MBP). Daily mean clinical scores and mortality rate were lower in this group
compared with controls. The proliferative responses of lymph node cells to rat MBP
were slightly less in the vaccination groups than in the control groups (p<0.05). How-
ever, we detected no differences between the two groups with regard to the produc-
tion of MBP-specific IgG, IgG1, & IgG2a antibodies. The levels of cytokine mRNA
expression in the vaccination groups were observed higher than in the control groups
without antigen-specific stimulation, but all of cytokine expressions between the
vaccination and control groups after antigen-specific stimulation were identical. These
results demonstrate that intradermal DNA vaccines encoding for TCR might prove
to be useful in the control of autoimmune disease.
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ed from The Jackson Laboratories (Bar Harbor, ME, U.S.A.),
and bred at the Memphis Veterans Administration Medical
Center Animal Research Facility. The animals were between
6 and 8 weeks old at the time of disease induction.
Antigen
MBP was prepared from frozen rat brains (Pel-Freez Bio-
logical, Rogers, AR) by the method developed by Smith (9).
In brief, the dissected rat brains were homogenized in 0.32
mol/L sucrose, then layered onto 0.85 mol/L sucrose. After
centrifugation (25,00 rpm for 30 min), the interface was care-
fully removed, washed three times with deionized water, and
lyophilized overnight. The protein was then resuspended in
90% acetone and stirred for 30 min at room temperature.
The precipitate was dried and redissolved in 10 mL 0.3 N
hydrochloric acid. The supernatant was carefully removed,
and dialyzed against 10 mM/L acetic acid. The acetic acid
was removed by lyophilization, and the MBP concentration
levels were deduced by 12% sodium dodecyl sulfate gel elec-
trophoresis. The SDS gel was stained with Coomassie Bril-
liant Blue R250 solution, and destained in acetic acid/metha-
nol (10% and 45% v/v, respectively). The total concentration
of the three major bands in the MBP protein (~16, ~19,
and ~21 kDa) were estimated based on the concentrations of
standard protein marker (GibcoBRL, Life Technologies,
Gaithersburg, MD, U.S.A.).
Plasmid construction 
cDNA from the 147 clone was used in this study (2). This
cDNA was employed in PCR using Taq polymerase (Strata-
gene, LaJolla, CA, U.S.A.) with primers specific for V 8.2
(5′ -CCG GAA TTC GCC GCC ACC ATG CAC ATG GAG
GCT GCA GTC ACC CAA-3′and 5′ -TGC TCT AGA
TTA GCT GGC ACA GAA GTA CAC TGA-3′ ). These
primers encompassed the entire V region (about 320 bp),
and included the EcoRI and XbaI sites used in cloning. The
amplified PCR products were subsequently cloned into the
pcDNA3.1 eukaryotic expression vector (Invitrogen, San
Diego, CA, U.S.A.), and sequenced, in order to verify the
insertion of the right gene into the appropriate open reading
frame.
DNA preparation and vaccination
Plasmid construct was prepared using Maxi Prep (Quiagen,
Chatsworth, CA, U.S.A.). There were two groups and each
group consists of twenty mice. B10.PL mice were injected
intradermally with 1-mL syringes and 28-gauge needles. Intra-
dermal inoculation was carried out 1-2 cm distal from the
tail base, with 300  g of pcDNA3.1 blank vector suspended
in 100  L PBS (control group), or an equal amount of the
mixed naked DNA encoding for the TCRV 8.2 (vaccination
group). Injections took place three times, at weekly intervals.
Induction and clinical evaluation of EAE
EAE was induced by a modification of the standard proto-
col (10). Twenty B10.PL mice of each group received subcu-
taneous injections of 200  g of rat MBP and killed Mycobac-
terium tuberculosis (H37RA, Difco, Detroit, MI, U.S.A.), at a
concentration of 3 mg/mL, in a 0.1-mL emulsion consisting
of equal volumes of 10 mM/L acetic acid and complete Fre-
und’s adjuvant (CFA). 300 ng of Bordetella pertussis toxin (List
Pharmaceuticals, Campbell, CA, U.S.A.) was administered
intraperitoneally 24 and 72 hr after MBP immunizations.
The mice were then observed daily for signs of EAE. The
scale used to grade the clinical status of the diseased mice was
as follows: 0, no clinical disease; 1, limp tail or hind limb
weakness; 2, limp tail and hind limb weakness; 3, partial hind
limb paralysis; 4, complete hind limb paralysis; 5, moribund
state. The mean clinical score in the study was defined as the
mean clinical score of all the animals. Mortality was expressed
as the percentage of animals that died as the result of severe
clinical EAE. The mean day of onset indicates the mean day
of the inception of signs of acute clinical disease in the mice
exhibiting clinical signs. The mean peak of disease severity
was evaluated as the mean of the highest clinical score achie-
ved by the mice exhibiting clinical signs.
Determination of rat MBP-specific IgG, IgG1 and IgG2b
antibodies
Blood was collected from both groups of mice three times,
at weeks 0 (first immunization), 2, and 3. The rat MBP-spe-
cific IgG, IgG1, and IgG2a antibody responses were assessed
by ELISA, as follows. One hundred microliters of rat MBP
(5  g/mL in 0.1 M carbonate buffer, pH 9.6) were dispensed
into each well of a polystyrene microtiter plate (Costar, Cam-
bridge, MA, U.S.A.), then incubated overnight at 4℃. The
antigen-coated plates were washed three times in 0.05% PBS-
Tween 20 buffer (washing buffer), and incubated with mice
sera at 4℃overnight. The plates were then washed five times
with washing buffer, and incubated with peroxidase-conju-
gated anti-mouse IgG antibody, goat anti-mouse IgG1, and
IgG2a (Sigma, St. Louis, MO, U.S.A.) overnight at 4℃. The
plates were then washed five times, prior to the addition of
citric acid-phosphate buffer (pH 5.0) containing 0.15 mg/
mL of O-phenylenediamine (Sigma). The color was devel-
oped at room temperature, and the reaction was discontin-
ued via the addition of 2.5 M sulfuric acid. The color was
the evaluated at a wavelength of 492 nm (Bio-Rad, Rich-
mond, CA, U.S.A.). 
Lymph node cell proliferation 
The proliferation assay was performed as described previ-ously (11). The lymph nodes were removed 10 days after
immunization with rat MBP, and single-cell suspensions were
prepared. The cells (2×105 cells per well) were then cultured
with serial dilutions of rat MBP (range, 0.01-10  g/mL).
Cultures were constructed in 200  L of RPMI1640, sup-
plemented with 10% fetal calf serum (Hyclone Laboratories,
Logan, UT, U.S.A.), 1 mM/L sodium pyruvate, 100  g/mL
penicillin, 100  g/mL streptomycin, 2 mM/L glutamine, 5×
10-5 M/L 2-mercaptoethanol, 20 mM/L HEPES (pH 7.4),
and 50× nonessential amino acids. After 4 days of cultur-
ing, 1  Ci of [3H] thymidine (Du Pont, Wilmington, DE,
U.S.A.) was added to each well. 18 hr later, the cells were
harvested and measured via the liquid scintillation counting
method. Values were expressed in counts per minute, as fol-
lows: Counts per minute with antigen - Counts per minute
without antigen. Each sample was assessed in triplicate in
this manner. RPMI medium 1640, sodium pyruvate, peni-
cillin, streptomycin, glutamine, HEPES, and 50×nonessen-
tial amino acids were purchased from Irvine Scientific (Santa
Ana, CA, U.S.A.), and 2-mercaptoethanol was purchased
from the Sigma Chemical Co.
Measuring the cytokine mRNA expression of lymph node
cells
Lymph node cells (1×107 cells per well) were cultured in
the presence of rat MBP (100  g/mL) in vitro for 18 hr. The
cells were washed with PBS buffer, and total RNA was ext-
racted with TRIzol Reagent (Biotecx, Houston, TX, U.S.A.).
By using murine leukemia virus reverse transcriptase and
random hexanucleotide primer, according to the instructions
provided in the Perkin-Elmer Gene Amp RNA PCR kit
(Perkin Elmer, Branchberg, NJ, U.S.A.), we generated first-
strand cDNA from 1  g of total RNA, and subjected it to
RT-PCR analysis. In order to determine the relative abun-
dance of the mRNA expression of each cytokine, the amount
of each cDNA for PCR was optimized according to the inten-
sity of the amplified DNA  -actin products generated from
each RNA. In the PCR reaction mixture, we added either
-actin as a control primer, IL-2, IFN- (Clonetech, PaloAl-
to, CA, U.S.A.), IL-4, or IL-5, at a final concentration of 0.2
M. The sequence of these primers is summarized in Table
1. The PCR conditions were as follows: 200  M of dNTP,
10 Ci  [32P] dCTP, 50  M Tris. HCl (pH 9.0), 50  M NaCl,
2 M  MgCl2, 0.5 mM DTT, and two units of Taq polymerase
(Perkin Elmer) at a final volume of 20  L. A negative con-
trol reaction was conducted with each sample, in order to
verify that no PCR bands appeared in the absence of the tem-
plate. The optimal amplification conditions were as follows:
denaturation for 45 sec at 94℃, annealing for 45 sec at 67℃,
and elongation for 1 min at 72℃. Our PCR protocol called
for 30 cycles. The amplified DNAs of  -actin, IFN- , IL-2,
IL-4, and IL-5, were 540, 365, 413, 354, 349, and 455 bp
in length, respectively. The gel was dried on Whatman 3M
paper, then exposed to Kodak XAR film. In each run of elec-
trophoresis, intra- and inter-gel staining homogeneity was
verified via assessments of the staining intensities of the molec-
ular weight markers at both ends of the gels. In general, the
amplification kinetics for each PCR run were monitored via
assessments of aliquots of the gel products. Amounts of PCR
products were compared during the cycle in which the ampli-
fication did not achieve saturation.
Statistical analysis
Significance of the differences in results was determined
by Student’s t-test for immunoglobulin production and pro-
liferation assays. In order to determine the severity of disease,
we utilized the Mann-Whitney test. A p value of <0.05 was
considered to be statistically significant.
RESULTS
Protective effects of vaccination with V 8.2 on the 
induction of EAE disease
The control group developed a more severe course of clin-
ical EAE than did the vaccination group. This was reflected
by higher daily mean clinical score (Fig. 1) and mortality
rate (50% vs. 0%) in the control group, after immunization
with whole MBP. However, no differences were observed
between groups with regard to the mean day of onset (21.67
±5.35 days vs. 18.67±3.88 days), or the mean peak severity
of disease (3.83±1.47 days vs. 2.51±0.54 days). These data
suggested that intradermal vaccination with V 8.2 might
exert a partially preventive effect on the induction of EAE
disease, after immunization with whole MBP.
Intradermal Vaccination with DNA Encoding T-cell Receptor 1041
Molecules
Product 
Size Primer Sequence (5′ to 3′ )
-actin 5′GTG GGC CGC TCT AGG CAC CAA 540 bp
3′CTC TTT GAT GTC ACG CAC GAT TTC
IL-2 5′TTC AAG CTC CAC TTC AAG CTC TAC  413 bp
AGC GGA AG
3′GAC AGA AGG CTA TCC ATC TCC TCA 
GAA AGT CC
IFN- 5′TGC ATC TTG GCT TTG CAG CTC TTC  365 bp
CTC ATG GC
3′TGG ACC TGT GGG TTG TTG ACC TCA 
AAC TTG GC
IL-4 5′CAG CTA GTT GTC ATC CTG CTC TTC 357 bp
3′GTG ATG TGG ACT TGG ACT CAT TCA TGG
IL-5 5′TGT CTG GGC CAC TGC CAT GGA GAT TC 424 bp
3′CCA TTG CCC ACT CTG TAC TCA TCA CAC
Table 1. Oligonucleotides used for cytokine mRNA expression
in this study1042 S.S. Kwon, N. Kim, T.-J. Yoo
MBP-specific IgG, IgG1 and IgG2a antibody production
by gene vaccination
IgG1 antibody depends on the interleukin (IL)-4 which is
secreted by the Th2 cells (12). Intradermal vaccination with
V 8.2 DNA (6.75±1.36 g/mL,  7.03±1.51 g/mL)  result-
ed in no different response with regard to MBP-specific IgG1
antibody, as compared with the control group (6.34±1.08
g/mL, 6.34±0.86  g/mL) at 2 and 3 weeks post-immu-
nization with whole MBP (p>0.05). IgG2a antibody forma-
tion is dependent on interferon- (IFN- ) as an IgM-to-IgG2a
switching factor, and is believed to be a typical Th1 response
(12). In regard to the response of MBP-specific IgG2a anti-
bodies, the vaccination group (14.65±1.85 g/mL,  14.64
±1.98  g/mL) did not significantly increase antibody pro-
duction, in comparison with the control group (12.66±1.06
g/mL, 12.80±1.00 g/mL)  (p>0.05). Also there were no
difference between the vaccination (1.41±0.16 mg/mL, 1.27
±0.22 mg/mL) and control groups (1.40±0.06 mg/mL,
1.39±0.06 mg/mL) with regard to the response of MBP-
specific total IgG antibodies (p>0.05). Thus, intradermal
genetic vaccination did not result in any differences from
the control group in terms of the production of antibodies
after immunization.
Cytokine gene expression by in vivo antigen stimulation
Even though the levels of mRNA expression of IFN- ,
IL-2, IL-4, & IL-5 in the vaccination group were observed
higher than in the control group without antigen-specific
stimulation, we detected no differences all of the cytokine
expressions between the two groups after antigen-specific
stimulation (Fig. 3). These data suggest that intradermal
DNA vaccination with V 8.2 DNA might not exert any
significant effects on the shift from the Th1-type cytokine
to the Th2-type cytokine.
Lymph node cell proliferation
On day 10 after immunization with the rat MBP in CFA,
the vaccination group’s proliferative responses to MBP of
lymph node cells was found to be significantly less pronounced
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Fig. 1. Preventive effects of DNA vaccination with TCR V 8.2 in
mice after active immunization with rat MBP on the induction of
EAE disease. The vaccination group (n=20) was intradermally
vaccinated with DNA encoding for the V 8.2 of the T-cell recep-
tor, three times at weekly intervals. The control group (n=20) was
injected with pcDNA 3.1 blank vector. After 3 weeks, all mice were
immunized with rat MBP. The clinical symptoms of EAE were mon-
itored and scored daily, as described in the Methods section. The
control group developed higher daily mean clinical score than the
vaccination group between days 20-25 (1.50±0.92, 1.63±0.74,
2.25±1.28, 3.0±1.07, 3.38±1.19, 3.5±1.41 vs. 0.13±0.35, 0.38
±0.52, 0.50±0.76, 1.00±1.07, 1.25±1.06, 1.13±1.36, p<0.05).
There was a dramatic reduction in mortality in the vaccination group
compared with controls; eight of sixteen mice died in the control
group, compared with none in the vaccination gorup (p<0.05).
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Fig. 2. The IgG1 (A), IgG2a (B), and IgG (C) antibody responses of the B10.PL mice immunized with rat MBP with DNA coding for V 8.2
or pcDNA only. Intradermal vaccination with V 8.2 DNA resulted in no different response with regard to MBP-specific IgG1 antibody, as
compared with the control group, at 2 and 3 weeks post-immunization with whole MBP (p>0.05). Also, with regard to the response of MBP-
specific IgG2a and IgG antibodies, the vaccination group did not significantly increase antibody production, in comparison with the con-
trol group (p>0.05). Sera of eigth mice in each group were collected three times on weeks 0, 2, and 3, after immunization. Data are expressed
as means±S.D. 
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than in the control group at antigen concentration 0.01  g/
mL, 0.1  g/mL, 1  g/mL, 100  g/mL (5082.08±933.21,
6759.33±1857.77, 10019.83±1494.50, 28228.83±
1699.82 vs. 10155.50±2096.45, 11504.49±718.14,
14861.50±1174.39, 32003.00±1734.84 dpm, p<0.05),
except 10  g/mL (14174.08±3337.39 vs. 18936.50±
2201.55 dpm, p>0.05) (Fig. 4). Intradermal vaccination with
DNA encoding for TCR V 8.2 might induce the suppres-
sion of lymph node cell proliferation, in response to MBP.
DISCUSSION
The potential advantages associated with DNA vaccina-
tion include the prolonged, endogenous expression of anti-
gens (5), long-term immunity with efficient generation of
both CD8+ cytotoxic T cells and CD4+ T helper cells (6, 7),
and the possibility of modulating Th1 or Th2 responses via
the alteration of vaccination protocols (13). It has also been
established that the in vivo transfection of the epidermis or
dermal cells by DNA would be expected to provide an effi-
cient route for gene immunization, due to immune response.
The present study sought to evaluate the effects of intrader-
mal vaccination with DNA encoding for TCR V 8.2, on
the induction of EAE in B10.PL mice, after the mice had
been immunized with whole MBP. This study appears to
have been extremely effective with regard to the induction
of EAE after immunization, as reflected by the mean daily
scores and mortality rate, even if the T-cell recognition of
MBP p35-47 does not involve the V 8.2 gene product (14).
The results of our present study confirm the results of an earlier
study, which reported that intradermal gene administration
induced a more profound immune response than did intra-
muscular gene delivery (5). 
Although immunization with the TCR peptide (3) and
vaccination with DNA (7, 15) also resulted in some protec-
tive effects on EAE development, little information is cur-
rently available regarding the mechanisms of action under-
lying the protection induced by DNA vaccination. A previ-
ous study reported that DNA vaccination resulted in a Th1
to Th2 cytokine shift, and then the Th2 cytokines suppressed
EAE development (7). However, another previous study de-
monstrated that there were no signs of a Th2 cytokine bias,
even if DNA vaccination did, indeed, suppress the develop-
Fig. 3. Cytokine gene expression. Four mice from each group were
sacrificed 10 days-after MBP immunization. Lymph node cells (1×
10
7 cells per well) were cultured either without antigen, or with rat
MBP (100  g/mL) in vitro, for 18 hr. The cells were washed with
PBS buffer and the total RNA was extracted using TRIzol reagent.
Using murine leukemia virus reverse transcriptase and random
hexanucleotide primer, according to the instructions of the Perkin
Elmer Gene Amp RNA PCR kit, first-strand cDNA was generated
from 1  g of total RNA and subjected to RT-PCR analysis. RT-PCR
reactions were then conducted using cDNA with different primers,
specific for  -actin, IL-2,  -interferon, IL-4, and IL-5. (1) Lymph
node cells from the control mice were cultured without antigen,
(2) or in the presence of rat MBP (100  g/mL). (3) Lymph node
cells from the vaccinated mice were cultured without antigen, (4)
or in the presence of rat MBP (100  g/mL). The levels of mRNA
expression of IFN- , IL-2, IL-4, & IL-5 in the vaccination groups
were observed higher than in the control groups without antigen-
specific stimulation, but there were no differences all of the cytokine
expressions between the two groups after antigen-specific stim-
ulation.
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Fig. 4. Lymph node cell proliferation 10 days after immunization,
the lymph nodes of four mice of each group were removed asepti-
cally, and single-cell suspensions were prepared. The cells (2×
10
5 cells per well) were then cultured with serial dilutions of rat MBP
(range, 0.01-100  g/mL). After 4 days of culturing, 1 Ci of [
3H]
thymidine was added to each well. 18 hr later, the cells were har-
vested, and measured via liquid scintillation counting. The vacci-
nation group's proliferative responses to MBP of lymph node cells
was found to be significantly less pronounced than in the control
group (p<0.05 at antigen concentrations 0.01-100  g/mL, except
10  g/mL). The values were expressed in counts per minute, as
follows: Counts per minute with antigen -Counts per minute without
antigen. *p<0.05 vaccination group compared with control group.
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Vaccination groupment of EAE (16). Furthermore, myelin/oligodendrocyte
glycoprotein-induced EAE was aggravated after the induc-
tion of Th2 immunity (17). In addition, IL-4-deficient mice,
which exhibit defective Th2 responses, could be tolerant to
the induction of EAE (18). The results of a RT-PCR analysis
on the total RNA samples extracted from the lymph node
cells also demonstrated that vaccination did not induce a Th1-
to-Th2 cytokine shift. In the case of MBP-induced immune
response, we determined there to be no difference between
the vaccination and control groups with regard to the response
of IgG1 & IgG2a antibodies in the present study. This study
indicated that intradermal vaccination with DNA encoding
for TCR V 8.2, in the case of EAE, did not induce a shift in
cytokine response from Th1 to Th2. Our findings were con-
sistent with other recent studies, which reported that the shift
from Th1 to Th2 cytokine responses is not directly involved
in protective effects against EAE.
In order to determine whether the observed protective
effects of gene vaccination were attributable to the deletion
of T cells or to the induction of unresponsiveness, we exam-
ined the proliferation of lymph node cells in proportion to
the MBP concentrations. In our study, we determined that
T cell proliferative responses against MBP in the vaccination
group were partially suppressed, compared to those in the
control group, but were higher in proportion to the MBP
concentration. T cell deletion has been observed primarily
after the administration of high doses of antigens or peptides
(19), and the presentation of antigens by nonprofessional
antigen-presenting cells (APCs) which lack co-stimulatory
capacity results in anergy, rather than in priming (20). How-
ever, professional APCs, Langerhans cells, or macrophages,
all of which are abundant in the dermis, may also function
as APCs after intradermal DNA vaccinations (5). It is also
possible that the intradermal gene vaccination in our study
might not have induced either T cell deletion or anergy.
Recently, it has been suggested that immunization with a
tolerogenic form of the antigen induces the generation of
regulatory CD4
+CD25
+ T cells, which, when activated either
by the antigen or by anti-idiotype-bearing transducer suppres-
sor cells, then served to mediate downmodulating T-helper
effect functions on other antigens present in conjunction with
the immunogen (21). However, the specificity or mechanisms
associated with regulatory CD4
+ T cell-mediated suppression
are not currently well understood. It has been reported, from
earlier studies, that DNA vaccines are efficient inducers of
regulatory CD8
+ T cell-mediated immunity, and that CD8
+
and MHC I-restricted effector T cells ultimately inhibit the
function of encephalitogenic V 8.2
+ T cells (22, 23). Also,
it is clear that the priming of the regulatory CD4 T cells must
occur in a Th1 milieu for the effective regulation of anti-MBP
responses, as well as protection from EAE. Furthermore, if
the regulatory CD4
+ T cells are compelled to deviate in the
direction of Th2 direction, this would result in the exacer-
bation of the disease, due principally to the absence of the
natural regulation provided by MBP-reactive T cells (24).
Recent reports suggest that protection from EAE after DNA
vaccination is predicated on immunostimulatory, unmethy-
lated CpG DNA motifs, and also that the underlying protec-
tive mechanism of DNA vaccination involves the immuno-
modulatory effects which are exerted by the induced IFN- ,
with no evidence for a shift in immune response toward the
production of type 2 cytokines (25). Also, IFN- exerts anti-
proliferative effects on peripheral blood monocytes. Our result
demonstrated that the levels of mRNA expression of IFN- ,
IL-2, IL-4, & IL-5 in the vaccination group were observed
higher than in the control group without antigen-specific
stimulation, but there were no differences in all of the cytokine
expressions between the two groups after antigen-specific
stimulation. This is consistent with the reports showing that
DNA vaccination activated T cells, B cells and dendritic cells
to produce a wide range of cytokines, but, DNA vaccination
induced the immunomodulation effect on the EAE after
antigen-specific stimulation (25). Therfore, we have deter-
mined that intradermal DNA vaccination does not result in
a shift from Th1 to Th2 cytokine responses, and also that T
cell proliferative responses against MBP after DNA vaccina-
tion were suppressed, as compared to what we observed in
the control group. This is consistent with earlier observations
(25). Although the observed protective autoimmune mech-
anisms underlying DNA vaccination in our study have yet
to be clearly established, we suggest that the mechanisms
underlying intradermal vaccination with V 8.2 DNA might
be associated with the immunomodulation exerted by the
induced IFN- .
In summary, genetic immunization is associated with several
advantages as compared with conventional vaccines, in that
genetic immunization makes it possible to express antigens
in forms which promote natural processing and presentation
to lymphocytes. Furthermore, DNA vaccines are safe, stable,
and induce long-lasting responses in host. Our present study
demonstrates that intradermal vaccination with DNA encod-
ing for the V 8.2 gene of the T-cell receptor might exert
inhibitory effects on the induction of EAE in mice. This study
suggests that intradermal vaccination with DNA encoding
for TCR might constitute a useful tool in the control of auto-
immune disease.
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